{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"23.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants having CR or PR as determined by investigator assessment of radiographic disease per RECIST v1.1. CR per RECIST v 1.1 was defined as disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. Per Cheson criteria, CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR: at least a 50% decrease in SPD of up to 6 of the largest dominant nodes or nodal masses. Per RANO criteria, CR: Complete disappearance of all enhancing measurable and non-measurable disease sustained. PR: at least ≥50% decrease compared with baseline in the SOD of all measurable enhancing lesions sustained.","groups":[{"description":"Participants received epacadostat 25 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 1, Part 1: Epacadostat 25 mg + Nivolumab 3 mg"},{"description":"Participants received epacadostat 50 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG001","title":"Phase 1, Part 1: Epacadostat 50 mg + Nivolumab 3 mg"},{"description":"Participants received epacadostat 100 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG002","title":"Phase 1, Part 1: Epacadostat 100 mg + Nivolumab 3 mg"},{"description":"Participants received epacadostat 300 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG003","title":"Phase 1, Part 1: Epacadostat 300 mg + Nivolumab 3 mg"}],"paramType":"NUMBER","populationDescription":"The Phase 1, Part 1 Full Analysis Population includes all participants enrolled in the study who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose up end of the study (up to approximately 6 years)","title":"Phase 1, Part 1: ORR Per RECIST v1.1 for Participants With Solid Tumors; Per Cheson Criteria for Participants With B-cell NHL; and Per RANO and mRANO Criteria for Participants With GBM","type":"SECONDARY","unitOfMeasure":"percentage of participants"}